自体NK细胞过继输注对Ⅲ-Ⅳ期NSCLC患者天然免疫与体力状态的影响

目的研究自体NK细胞过继输注对晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者天然免疫及体力状况(performance status, PS)评分的影响。方法 应用流式细胞仪检测20例晚期NSCLC患者(肺癌组)和20例健康人(健康对照组)外周血NK(CD16+CD56+)细胞的表达水平；检测晚期NSCLC患者应用自体NK细胞过继输注后外周血NK(CD16+CD56+)细胞的表达水平。根据美国东部肿瘤协作组(Eastern Cooperative Oncology Group, ECOG)体力状况评分标准,比较肺癌组患者应用自体NK细胞过继输注前后PS评分的变化情况。结果 外周血NK(CD16+CD56+)细胞的表达明显降低[(8.980±1.942)%],与健康对照组[(15.290±1.869)%]比较差异均有统计学意义(P＜0.05)。肺癌组治疗前PS评分为(1.50±1.080),应用自体NK细胞过继输注后PS评分显著降低(1.00±0.816),外周血NK(CD16+CD56+)细胞的表达显著升高[(24.660±10.049)%],与治疗前比较,差异均有统计学意义(P＜0.05)。结论 自体NK细胞过继免疫治疗有助于提高晚期NSCLC患者的免疫功能状态及体力状况。
Objective To investigate the immune function and performance score of patients with advanced non-small cell lung cancer(NSCLC) before and after adoptive transfer of autologous NK cells. Methods Twenty patients with stage Ⅲ-Ⅳ NSCLC(Lung cancer group) undergoing adaptive autologous NK cells and 20 healthy subjects(control group) were enrolled in the study. Peripheral blood NK cells(CD16+CD56+)were detected with flow cytometry, and the Eastern Cooperative Oncology Group(ECOG) performance scores(PS) were evaluated before and after the adoptive NK therapy. Results Before adaptive therapy the peripheral blood NK(CD16+CD56+)levels in NSCLC patients were significantly lower than those in controls [(8.980±1.942)% vs(15.290±1.869)%, P<0.05]. The PS was decreased from(1.50±1.080) to(1.00±0.816)(P<0.05); and the peripheral blood NK levels was increased to(24.660±10.049)%] after adoptive therapy(P<0.05). Conclusion Autologous NK cells adoptive immunotherapy may improve the immune function and performance status in patients with advanced non-small cell lung cancer